Holy Name Press Releases

Holy Name Welcomes Renowned Surgical Oncologist George Miller, MD

As Division Chief of Surgical Oncology and Medical Director of Oncologic Surgery

July 26, 2023

George Miller, MD, has joined Holy Name as the Division Chief of Surgical Oncology and the Medical Director of Oncologic Surgery. Dr. Miller, certified by the American Board of Surgery, is one of the nation's leading surgeon-investigators, with a distinguished career as an accomplished physician-leader. He is a highly experienced surgical oncologist recognized for his expertise in the treatment of gastrointestinal cancers, especially those affecting the liver, pancreas, and upper GI tract.

Working in the new office of Holy Name Surgical and Oncology Specialists at Holy Name Medical Center, Dr. Miller will lead a growing team of expert cancer surgeons and oversee a wide range of specialized cancer care services, calling upon his intensive training and experience as a surgical oncologist.

"Dr. Miller is an innovative and incredibly talented surgical oncologist with a comprehensive understanding of effective treatment practices and precision techniques. He is known as an avid devotee of emerging technologies that can improve patient outcomes," said Michael Maron, President and CEO, Holy Name. "We're excited to have him here and our patients will benefit from his surgical expertise."

Dr. Miller joins Holy Name from Trinity Health of New England, a four-hospital consortium in Connecticut and Massachusetts, where he directed surgical oncology services since 2021. As a surgical oncologist he has performed more than 400 major liver resections and 350 pancreatectomies. Prior to joining Trinity Health Of New England, Dr. Miller was an oncology surgeon at New York University Medical Center and Bellevue Hospital Center. Dr. Miller has also served as Chair of Surgery at NYU-affiliated Woodhull Hospital.

He completed his residency training in general surgery at NYU and a trio of fellowships at Memorial Sloan Kettering Cancer Center in surgical oncology, hepatobiliary-pancreatic surgery, and experimental immunology. Dr. Miller was on the faculty of NYU School of Medicine for 14 years where he was the inaugural HL Pachter Professor of Surgery and Cell Biology. Dr. Miller was vice-chair of NYU's surgery department, leader of NYU's 35-member National Cancer Institute-designated Tumor Immunology Program, co-leader of NYU's GI Disease Management Group, and director of the nation's only T32 NCI Training grant in Gastrointestinal Oncology.

"I'm thrilled to join Holy Name, where clinical excellence is combined with truly patient-centered care," said Dr. Miller, "Holy Name continues to transform how high quality healthcare is delivered, and I look forward to playing a major part in that pioneering effort to improve patients' lives."

Dr. Miller has been recognized with several prestigious awards from organizations such as the Society of University Surgeons, the American Liver Foundation and the American Association for Cancer Research, as well as the Ruth Leff Siegel Award given annually to scientists making the most important contribution to pancreatic cancer research. His research has been published in leading journals including Nature, Nature Medicine, Cancer Discovery, and Cell and his work has been translated to four Phase I clinical trials. He has also developed an array of new cancer therapeutics that have entered clinical testing and has co-founded a successful start-up company focusing on the development of novel immune-based therapies. His work has led to more than 40 provisional patent applications. His seminal work includes contributions to the roles of the microbiome, innate immunity, and inflammatory cell death in oncogenesis. Dr. Miller is also a highly recognized lecturer and keynote speaker in the field of cancer research and oncologic surgery.